Dynorphin
Also known as: Big Dynorphin, Dynorphin (1‑13), Dynorphin A, Dynorphin B, Dynorphin‑1, Dynorphin‑2, Leu-enkephalin-Arg, PDYN-derived peptide
Source Dynorphin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Dynorphin is an endogenous opioid peptide belonging to the dynorphin family. It acts primarily as an agonist at κ‑opioid receptors and is found throughout the central nervous system. Research links dynorphin to the regulation of pain, stress, sleep, and reproductive hormone release, and it is investigated in contexts such as menopause‑related sleep disturbance, addiction neurocircuitry, and opioid‑induced hyperalgesia. The peptide is currently a research tool rather than an approved therapeutic.
Mechanism of Action
Dynorphin binds and activates κ‑opioid receptors (KORs), leading to inhibition of adenylate cyclase, reduced cAMP, and modulation of ion channels that dampen neuronal excitability. In the hypothalamus, dynorphin is co‑expressed with kisspeptin and neurokinin B in KNDy neurons, where it provides negative feedback on gonadotropin‑releasing hormone (GnRH) secretion. KOR activation also interacts with dopamine pathways, corticotropin‑releasing factor, and NMDA‑receptor systems, contributing to stress responses, dysphoria, and altered pain perception.
What the Research Shows
A 2024 review of menopause‑related sleep disturbance highlights the role of hypothalamic kisspeptin/neurokinin B/dynorphin (KNDy) neurons in integrating reproductive, temperature, and circadian signals, suggesting dynorphin as a target for future therapies. A 2022 endocrine review describes KNDy neurons, noting dynorphin’s participation in estrogen feedback on GnRH and its influence on puberty and fertility. A 2004 study on electroacupuncture reports that high‑frequency stimulation selectively increases dynorphin release, contributing to analgesia. A 2016 neurobiology of addiction paper links dynorphin recruitment in the extended amygdala to negative emotional states during drug withdrawal. Finally, a 2024 anaesthesiology review associates elevated dynorphin levels with remifentanil‑induced hyperalgesia, implicating KOR activation in opioid‑related pain sensitisation. Across these sources, evidence is largely mechanistic or pre‑clinical, with no human clinical trials of exogenous dynorphin.
Reported Benefits
Preclinical data suggest dynorphin modulation could influence several physiological processes: (1) regulating GnRH release and thus reproductive hormone balance; (2) affecting sleep‑wake circuitry via hypothalamic pathways; (3) providing analgesic effects when released endogenously, as seen with high‑frequency electroacupuncture; (4) offering a target for mitigating stress‑related aspects of addiction withdrawal; and (5) informing strategies to prevent opioid‑induced hyperalgesia. These potential benefits remain theoretical pending translational studies.
Limitations of the Evidence
Evidence for therapeutic use of dynorphin is limited to animal models, mechanistic reviews, and indirect observations. Direct administration of dynorphin has not been tested in humans, and κ‑opioid agonism can produce dysphoria, anxiety, and stress‑like responses, which may counteract any analgesic benefit. The peptide’s short half‑life and poor blood‑brain barrier penetration pose formulation challenges. Conflicting roles—analgesic versus hyperalgesic—highlight an incomplete understanding of dose‑response relationships.
Safety Considerations
Activation of κ‑opioid receptors by dynorphin is associated with dysphoric and anxiogenic effects in humans and animals. Elevated dynorphin contributes to stress circuitry activation, withdrawal‑related negative affect, and opioid‑induced hyperalgesia. No safety data exist for exogenous dynorphin administration; thus, any translational approach would need careful monitoring for mood disturbances, heightened pain sensitivity, and cardiovascular effects linked to central opioid modulation.
How It Is Administered
Research studies have delivered dynorphin via intracerebroventricular, intrathecal, or intravenous routes in animal models to assess central effects. Endogenous release can be stimulated by high‑frequency electroacupuncture. No approved pharmaceutical formulations or dosing regimens exist for human use.
Routes of Administration
Goals & Uses
- Stress and mood researchPsychiatry / NeuroscienceHigh
- Pain modulation researchResearchHigh
- Addiction and reward pathway researchAddiction / NeuroscienceModerate
- stress resiliencePsychiatricLow
- Spinal cord injury / neuroprotection researchNeuropathologyLow
- Neuroendocrine regulation researchEndocrinology / NeuroscienceModerate
- AnalgesiaPain ManagementModerate
- anti‑addictionSubstance Use DisorderLow
Contraindications
- Systemic administration in humans (therapeutic use)Clinical SafetyHigh
- Known hypersensitivity to dynorphin peptidesAllergy / ImmunologyHigh
Adverse Effects
- Cardiovascular depressionCardiovascularUncommon
- DysphoriaPsychiatricCommon
- HypotensionCardiovascularUncommonLow blood pressure
- DiuresisRenalCommon
- Neurotoxicity (high doses, spinal)NeurologicalRare
- SedationCNSCommon
Drug Interactions
- KOR antagonists (e.g., nor-BNI, JDTic)Low
- mu‑opioid agonists (e.g., morphine)Moderate
- KOR antagonists (e.g., naloxone, nor‑BNI)High
- Naloxone / NaltrexoneModerate
- Mu-opioid agonists (e.g., morphine, fentanyl)Moderate
Population Constraints
- Pregnant or lactating individualsReproductiveAbsolute
- Individuals with psychiatric disordersPsychiatricRelative
- Human subjects (general)Clinical PopulationAbsolute
Regulatory Status
- European UnionUnapprovedResearch‑grade material.
- United StatesUnapprovedAvailable only for research use.
- United KingdomUnapprovedResearch use only.
Not approved as a therapeutic agent in any jurisdiction; supplied for laboratory research only.
Evidence & Sources
- Journal ArticleModerateMaki PM, Panay N, Simon JA2024-01-01T00:00:00.000000Z
- Journal ArticleModerateXie Q, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleModerateHan JS2004-01-01T00:00:00.000000Z
- Journal ArticleModerateKoob GF, Volkow ND2016-01-01T00:00:00.000000Z
- Journal ArticleModerateVitin AA, Egan TD2024-01-01T00:00:00.000000Z
Frequently Asked Questions
What is dynorphin’s primary receptor target?
Dynorphin is a selective agonist of the κ‑opioid receptor (KOR), a G‑protein‑coupled receptor that modulates neurotransmitter release, pain perception, and stress responses.
Can dynorphin be used to treat menopause‑related sleep problems?
Current evidence is limited to mechanistic reviews indicating that dynorphin‑containing KNDy neurons influence sleep circuitry. No clinical trials have tested dynorphin‑based therapies for menopausal sleep disturbance.
Why might dynorphin contribute to opioid‑induced hyperalgesia?
Studies suggest that abrupt cessation of potent opioids like remifentanil raises central dynorphin levels, activating KORs that can enhance NMDA‑receptor activity and spinal facilitation, leading to heightened pain sensitivity.
Is dynorphin involved in addiction or withdrawal?
Neurocircuitry analyses link dynorphin release in the extended amygdala to the negative emotional state experienced during drug withdrawal, indicating a role in the stress component of addiction.
How is dynorphin released during acupuncture?
High‑frequency (≈100 Hz) electroacupuncture has been shown to selectively increase dynorphin release in the central nervous system, contributing to the analgesic effect observed in some pain studies.
What is Dynorphin used for?
Dynorphin is educationally associated with: Stress and mood research, Pain modulation research, Addiction and reward pathway research, stress resilience, Spinal cord injury / neuroprotection research, Neuroendocrine regulation research, Analgesia, anti‑addiction. Educational only — not medical advice.
How is Dynorphin administered?
Recorded routes of administration: Intracerebroventricular, Intrathecal, Intravenous, Subcutaneous.
What are the potential side effects of Dynorphin?
Reported adverse effects include: Cardiovascular depression, Dysphoria, Hypotension, Diuresis, Neurotoxicity (high doses, spinal), Sedation. This list is not exhaustive — consult a qualified clinician.
Who should avoid Dynorphin?
Recorded contraindications: Systemic administration in humans (therapeutic use), Known hypersensitivity to dynorphin peptides. Consult a qualified clinician before use.